A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma

Trial Profile

A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Astrocytoma; Liver cancer; Medulloblastoma; Neuroblastoma; Rhabdomyosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Mar 2016 Protocol amended as treatment arms changed from 1 to 5 as reported by ClinicalTrials.gov.
    • 25 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 05 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top